OLEMA PHARMACEUTICALS INC (OLMA) Stock Income Statement
NASDAQ:OLMA - US68062P1066 - Common Stock
5.77 USD
+0.23 (+4.15%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 157.13M | 142.26M | 104.96M | 106.99M | 71.49M | |||
| Research and Development | 140.05M | 124.52M | 86.14M | 82.27M | 51.10M | |||
| Selling, General, and Administrative Expenses | 17.07M | 17.74M | 18.82M | 24.71M | 20.39M | |||
| Operating Income | -157.13M | -142.26M | -104.96M | -106.99M | -71.49M | |||
| Interest Income/Expense | 14.79M | 12.68M | 8.32M | 2.23M | 440.00K | |||
| Other Income/Expense | 43.00K | 102.00K | -19.00K | -30.00K | -50.00K | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -142.29M | -129.47M | -96.66M | -104.79M | -71.10M | |||
| Net Income | -142.29M | -129.47M | -96.66M | -104.79M | -71.10M | |||
| EBITDA | -156.66M | -141.87M | -104.58M | -106.63M | -71.33M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.92 | -2.20 | -2.14 | -2.62 | -1.80 | |||
| Non GAAP EPS | -1.98 | -2.21 | -2.16 | -2.62 | -1.80 | |||
| Statistics | ||||||||
All data in USD